This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • Epirubicin as 2nd line treatment to patients with ...
Clinical trial

Epirubicin as 2nd line treatment to patients with TOP2A gene amplified and oxaliplatin refractory metastatic colerectal cancer

Read time: 1 mins
Last updated:22nd Jul 2013
To assess the Progression-free survival
Category Value
Study start date 2013-07-22

View full details